文献速递甲状腺疾病

消融前刺激状态下甲状腺球蛋白对甲状腺癌预后的预测价值:2500例回顾性分析

Prognostic Implications of Preablation Stimulated Tg: A Retrospective Analysis of 2500 Thyroid Cancer Patients.
PubMed 文献 · J Clin Endocrinol Metab · 2021-01-01

该研究回顾性分析了2524例接受全甲状腺切除和放射性碘消融的分化型甲状腺癌(DTC)患者,评估消融前刺激状态下甲状腺球蛋白(ps-Tg)与持续/复发疾病的关系。多因素分析显示ps-Tg是独立预测因子,ps-Tg≤10.1 ng/mL预测无病状态的阴性预测值为95%,将其纳入ATA风险分层可更准确预测临床结局。

要点

  • ps-Tg≤10.1 ng/mL对无病状态有95%的阴性预测价值。
  • ps-Tg是持续/复发疾病的独立预测因子。
  • 将ps-Tg纳入ATA风险分层可改善中高危患者的预后评估。

核心结论

  • ps-Tg≤10.1 ng/mL是DTC患者临床结局的关键预测因子。
  • 将ps-Tg纳入ATA风险分层系统可更准确预测临床结局。

研究设计与样本

  • 回顾性分析2006至2018年间接受全甲状腺切除和放射性碘消融的2524例DTC患者病历。
  • ps-Tg在残留消融前甲状腺激素撤退状态下测量。

主要发现

  • 多因素分析中,年龄、ATA风险分层、远处转移、ps-Tg和累积给药活度是持续/复发疾病的独立预测因子。
  • ROC分析确定ps-Tg截断值≤10.1 ng/mL预测无病状态,阴性预测值为95%,并在所有ATA类别中验证。
  • 将ps-Tg整合入ATA风险类别显示,ps-Tg≤10.1 ng/mL与中危和高危患者持续/复发疾病概率显著降低相关(中危从9.9%降至4.1%,高危从33.1%降至8.5%)。

关键数值与推荐

  • ps-Tg≤10.1 ng/mL预测无病状态的阴性预测值为95%。
  • 中危患者中,ps-Tg≤10.1 ng/mL者持续/复发疾病概率从9.9%降至4.1%。
  • 高危患者中,ps-Tg≤10.1 ng/mL者持续/复发疾病概率从33.1%降至8.5%。

临床怎么用

  • 对于接受全甲状腺切除和放射性碘消融的DTC患者,可考虑测量消融前刺激状态下甲状腺球蛋白(ps-Tg)。
  • ps-Tg≤10.1 ng/mL可作为预测无病状态的有用指标,辅助ATA风险分层进行更个体化的预后评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: The risk of persistent and recurrent disease in patients with differentiated thyroid cancer (DTC) is a continuum that ranges from very low to very high, even within the 3 primary risk categories. It is important to identify independent clinicopathological parameters to accurately predict clinical outcomes. OBJECTIVE: To examine the association between pre-ablation stimulated thyroglobulin (ps-Tg) and persistent and recurrent disease in DTC patients and investigate whether incorporation of ps-Tg could provide a more individualized estimate of clinical outcomes. DESIGN, SETTING, AND PARTICIPANTS: Medical records of 2524 DTC patients who underwent total thyroidectomy and radioiodine ablation between 2006 and 2018 were retrospectively reviewed. MAIN OUTCOME MEASURE: Ps-Tg was measured under thyroid hormone withdrawal before remnant ablation. Association of ps-Tg and clinical outcomes. RESULTS: In multivariate analysis, age, American Thyroid Association (ATA) risk stratification, distant metastasis, ps-Tg, and cumulative administered activities were the independent predictive factors for persistent/recurrent disease. Receiver operating characteristic analysis identified ps-Tg cutoff (≤10.1 ng/mL) to predict disease-free status with a negative predictive value of 95%, and validated for all ATA categories. Integration of ps-Tg into ATA risk categories indicated that the presence of ps-Tg ≤ 10.1 ng/mL was associated with a significantly decreased chance of having persistent/recurrent disease in intermediate- and high-risk patients (9.9% to 4.1% in intermediate-risk patients, and 33.1% to 8.5% in high-risk patients). CONCLUSION: The ps-Tg (≤10.1 ng/mL) was a key predictor of clinical outcomes in DTC patients. Its incorporation as a variable in the ATA risk stratification system could more accurately predict clinical outcomes.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Tian T, Xu Y, Zhang X, et al. Prognostic Implications of Preablation Stimulated Tg: A Retrospective Analysis of 2500 Thyroid Cancer Patients. J Clin Endocrinol Metab. 2021. PMID: 34143886. doi:10.1210/clinem/dgab445

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。